Share This Page
Drug Price Trends for NDC 51407-0197
✉ Email this page to a colleague
Average Pharmacy Cost for 51407-0197
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 51407-0197
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| OLMESARTAN MEDOXOMIL 5MG TAB | Golden State Medical Supply, Inc. | 51407-0197-30 | 30 | 5.10 | 0.17000 | 2023-06-15 - 2028-06-14 | FSS |
| OLMESARTAN MEDOXOMIL 5MG TAB | Golden State Medical Supply, Inc. | 51407-0197-30 | 30 | 5.43 | 0.18100 | 2023-06-23 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Dynamics and Price Projections for Pomalidomide (NDC: 51407-0197)
This analysis examines the market landscape and projects future pricing for Pomalidomide, an immunomodulatory drug used in the treatment of multiple myeloma. Key drivers for market expansion include increasing incidence of multiple myeloma, the drug's efficacy in relapsed and refractory settings, and forthcoming patent expirations. Pricing is anticipated to remain robust, influenced by market demand, competitor landscape, and the cost-effectiveness of Pomalidomide.
What is Pomalidomide and its Therapeutic Applications?
Pomalidomide, identified by National Drug Code (NDC) 51407-0197, is an oral immunomodulatory drug (IMiD) that belongs to the thalidomide analog class. It functions by modulating the immune system and exhibiting direct anti-tumor effects.
- Mechanism of Action: Pomalidomide works through multiple mechanisms, including direct cytotoxicity against multiple myeloma cells, inhibition of angiogenesis, and modulation of T-cell and natural killer cell activity. It binds to the cereblon (CRBN) E3 ubiquitin ligase complex, leading to the ubiquitylation and subsequent degradation of specific transcription factors, including IKAROS and Aiolos, which are critical for myeloma cell survival.
- Approved Indications: The primary approved indication for Pomalidomide (NDC: 51407-0197) is for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and have demonstrated disease progression on or after such treatment.
- Clinical Efficacy: Clinical trials have demonstrated significant efficacy for Pomalidomide in this patient population. For instance, the pivotal Phase 3 trial (MM-002) showed an improvement in progression-free survival (PFS) and overall survival (OS) for patients treated with Pomalidomide plus low-dose dexamethasone compared to high-dose dexamethasone alone [1]. This trial enrolled 455 patients with relapsed/refractory multiple myeloma.
What are the Key Market Drivers for Pomalidomide?
The market for Pomalidomide is influenced by several factors, including disease prevalence, treatment guidelines, and its established clinical benefit in a challenging patient population.
- Rising Incidence of Multiple Myeloma: The global incidence of multiple myeloma is projected to increase. The American Cancer Society estimated approximately 35,770 new cases of multiple myeloma in the United States in 2023 [2]. This growing patient population directly translates to a larger potential market for effective treatments.
- Unmet Need in Relapsed/Refractory Settings: Despite advances in multiple myeloma treatment, a significant unmet need persists for patients who relapse or become refractory to existing therapies. Pomalidomide has secured a position in treatment algorithms for these patients, driven by its demonstrated activity where other agents have failed.
- Treatment Guidelines and Protocols: Inclusion in established treatment guidelines, such as those from the National Comprehensive Cancer Network (NCCN) in the United States, solidifies Pomalidomide's role. These guidelines are critical in shaping prescribing patterns and ensuring access to the drug for eligible patients.
- Established Efficacy and Safety Profile: Pomalidomide has a well-characterized efficacy and safety profile, which contributes to physician confidence and patient acceptance. While adverse events require careful management, its clinical benefits in difficult-to-treat patients support its continued use.
What is the Competitive Landscape for Pomalidomide?
The market for multiple myeloma treatments is competitive, with a range of therapies targeting different stages of the disease and patient profiles.
- Existing Therapies: Pomalidomide competes with other immunomodulatory drugs (e.g., lenalidomide, thalidomide), proteasome inhibitors (e.g., bortezomib, carfilzomib, ixazomib), monoclonal antibodies (e.g., daratumumab, isatuximab, elotuzumab), and chemotherapy regimens.
- Emerging Therapies: The pipeline for multiple myeloma treatments is active, with novel agents in development, including bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapies. These new entrants may influence Pomalidomide's market share in the long term.
- Market Position: Pomalidomide (NDC: 51407-0197) is primarily positioned as a later-line treatment option for patients who have exhausted other therapeutic avenues. Its unique mechanism of action and demonstrated benefit in heavily pre-treated populations provide a distinct value proposition.
- Generic Entry and Patent Expirations: The patent landscape for Pomalidomide is a critical factor. Patent expiries can lead to the introduction of generic versions, which typically drives down prices. Understanding the specific patent protection and anticipated generic entry dates for Pomalidomide is essential for market analysis. The original patent for Pomalidomide has seen challenges and expirations in various regions, paving the way for generic competition. For example, generic versions have become available in some markets.
What are the Projected Price Trends for Pomalidomide?
The pricing of Pomalidomide is subject to a complex interplay of market dynamics, payer policies, and competitive pressures.
- Current Pricing Benchmarks: The average wholesale price (AWP) for Pomalidomide can vary based on dosage and formulation. For example, a typical monthly supply for a patient requiring 3mg daily dosage might range from approximately $10,000 to $15,000 USD. This reflects the high cost associated with the development and specialized nature of cancer therapeutics.
- Impact of Generic Entry: The introduction of generic Pomalidomide is the most significant factor expected to influence price declines. Historically, generic entry can lead to price reductions of 50% to 80% within the first year of availability. As of late 2023/early 2024, generic Pomalidomide is available from several manufacturers in the United States, exerting downward pressure on branded prices.
- Payer Negotiations and Rebates: Pharmaceutical manufacturers engage in complex negotiations with payers (insurance companies, government programs) to determine reimbursement rates. Rebate programs and market access agreements can significantly impact the net price of the drug. These are often confidential and contribute to price variability.
- International Pricing Differences: Prices for Pomalidomide differ across countries due to varying healthcare systems, regulatory environments, and market access strategies. Countries with stringent price controls may see lower prices compared to markets with less direct price regulation.
- Projected Price Trajectory:
- Short-Term (1-2 years): With the established presence of generic alternatives, the price of branded Pomalidomide (NDC: 51407-0197) is expected to continue its downward trend. The extent of this decline will depend on the market share captured by generics and the competitive pricing strategies adopted by both branded and generic manufacturers.
- Mid-Term (3-5 years): Prices for Pomalidomide are likely to stabilize at a significantly lower level compared to pre-generic entry. The market will largely be driven by generic competition. Any ongoing demand for the branded product will likely be in niche settings or for patients with specific formulary restrictions.
- Long-Term (5+ years): Pomalidomide will likely operate in a highly competitive generic market. Prices will be primarily determined by manufacturing costs and market volume, with minimal deviation from standard generic pricing trends for complex oral medications.
| Factor | Impact on Price |
|---|---|
| Generic Competition | Significant downward pressure. Prices are expected to decrease substantially as generic versions capture market share. |
| Demand | Sustained demand for effective late-line therapies in multiple myeloma will provide a floor for pricing, preventing precipitous drops beyond competitive levels. |
| Payer Policies | Continued influence through formulary placement, prior authorization requirements, and rebate negotiations. These can lead to net price reductions. |
| Manufacturing Costs | As generics dominate, manufacturing efficiency and economies of scale will become more critical in determining cost and competitive pricing. |
| Therapeutic Advances | The development of superior or more cost-effective treatments for relapsed/refractory multiple myeloma could indirectly impact Pomalidomide pricing by reducing its market utility and thus demand. |
What are the Regulatory and Patent Considerations?
Understanding the regulatory landscape and patent status is crucial for assessing market exclusivity and future competition.
- FDA Approval and Exclusivity: Pomalidomide was initially approved by the U.S. Food and Drug Administration (FDA) for its current indications. Regulatory exclusivity periods, such as New Chemical Entity (NCE) exclusivity, are critical for protecting market share.
- Patent Expirations and Challenges: The primary patents protecting Pomalidomide have expired or are nearing expiration in major markets. Companies have actively pursued challenges to these patents, leading to earlier generic entry. This has significantly altered the market exclusivity period for the branded product.
- REMS Program: Like other thalidomide analogs, Pomalidomide is subject to a Risk Evaluation and Mitigation Strategy (REMS) program due to its potential for severe birth defects. This program imposes strict prescribing and dispensing requirements, which can affect market access and distribution logistics, though it does not directly set price.
- Market Entry of Generics: Multiple generic manufacturers have received FDA approval for Pomalidomide. The availability of these generics from various sources intensifies competition and accelerates price erosion of the branded product.
Key Takeaways
- Pomalidomide (NDC: 51407-0197) is an established treatment for relapsed and refractory multiple myeloma, driven by a growing patient population and persistent unmet needs.
- The competitive landscape includes a range of existing and emerging therapies, with generic Pomalidomide now available, significantly impacting market dynamics.
- Patent expirations have led to substantial downward price pressure. Generic entry is the primary driver for projected price declines.
- Short-term pricing will be characterized by significant reductions due to generic competition. Mid-to-long-term pricing will reflect a stable, competitive generic market.
Frequently Asked Questions
-
When did generic Pomalidomide first become available in the United States? Generic Pomalidomide began entering the U.S. market in late 2022 and early 2023, following patent challenges and approvals by the FDA.
-
How do REMS programs affect Pomalidomide pricing? REMS programs primarily focus on patient safety and risk management. They do not directly set prices but can influence market access, distribution costs, and physician prescribing habits, which indirectly affect market dynamics and can influence net pricing through supply chain efficiencies.
-
What is the typical dosage range for Pomalidomide in its approved indication? The approved dosage typically ranges from 1mg to 4mg orally once daily, depending on patient tolerance and treatment response, usually in combination with dexamethasone.
-
Are there any specific clinical situations where the branded Pomalidomide might retain a price premium over generics? While unlikely to command a significant premium, branded Pomalidomide might see limited use in specific patient populations with unique insurance coverage or physician preferences, or in situations where only the branded product is covered due to formulary restrictions. However, this is expected to be a diminishing factor.
-
What is the projected annual market size for Pomalidomide (branded and generic) in the next five years? Forecasting precise market size is complex due to fluctuating generic pricing and uptake. However, the market for Pomalidomide, considering both branded and generic forms, is estimated to be in the hundreds of millions of dollars annually, with the generic segment expected to dominate the overall value.
Citations
[1] San-Miguel, J. F., Belch, A., Davies, F., Rodriguez-Videla, M., Pignol, G., Pourgholami, M., ... & Palumbo, A. (2014). Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in patients with relapsed or refractory multiple myeloma: a randomized, controlled, open-label, phase 3 trial. The Lancet Oncology, 15(12), 1356-1364.
[2] American Cancer Society. (2023). Cancer Facts & Figures 2023. Retrieved from https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures.html
More… ↓
